Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biosplice Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: https://www.biosplice.com/d...
Year Founded: 2007
Status: Private
BioCentury | Oct 29, 2024
Management Tracks
Biogen names new CFO, CMO
Plus management updates at Ottimo, Genascence, Pll, Nabsys 2.0 and Arbutus
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Jun 18, 2024
Deals
Deals Report: Syncona merging Freeline, SwanBio to form Spur
Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more
BioCentury | Nov 28, 2022
Management Tracks
Biosplice’s Beaupre becomes CMO at Ideaya
Plus: Blaine Davis named CFO at Selecta, and updates from Promontory, ARTHEx and Shionogi
BioCentury | Nov 12, 2022
Regulation
Nov. 11 Quick Takes: FDA approves Imfinzi for metastatic NSCLC
Plus: Livtencity expands its territory to European markets, and updates from Apexigen, Biosplice and Avstera
BioCentury | May 12, 2022
Management Tracks
Siegall resigns as Umoja chair
Plus short stay for new Moderna CFO and updates from CSL Plasma, Spectrum, Pharvaris, Xequel and more
BioCentury | Feb 24, 2022
Management Tracks
Philip to succeed Marrazzo at Spark
Plus LaCaze joins Mnemo and updates from Sumitomo, Veracyte, Totus and more
BioCentury | Sep 16, 2021
Finance
Sept. 15 Quick Takes: Strong appetite for Tyra, DICE IPOs
Plus: Twist-Adicet and Haisco-Biosplice
BioCentury | Apr 17, 2021
Deals
April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more
The FTC has cleared the $39 billion takeout of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc (LSE:AZN; NASDAQ:AZN), clearing a hurdle for the pharma at a time when biopharma
Items per page:
1 - 9 of 9